Published in Antimicrob Agents Chemother on August 01, 2011
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology (2013) 1.66
3'-processing and strand transfer catalysed by retroviral integrase in crystallo. EMBO J (2012) 1.49
The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology (2014) 1.34
Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother (2013) 1.29
What if HIV were unable to develop resistance against a new therapeutic agent? BMC Med (2013) 1.27
Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother (2012) 1.24
Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother (2013) 1.21
Retroviral integrase proteins and HIV-1 DNA integration. J Biol Chem (2012) 1.20
Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness. Antimicrob Agents Chemother (2013) 1.17
Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet (2013) 1.12
Novel therapeutic strategies targeting HIV integrase. BMC Med (2012) 1.06
Current perspectives on HIV-1 antiretroviral drug resistance. Viruses (2014) 1.04
The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs. Mol Biol Int (2012) 1.03
Is resistance to dolutegravir possible when this drug is used in first-line therapy? Viruses (2014) 0.96
Inhibiting the HIV integration process: past, present, and the future. J Med Chem (2013) 0.93
Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review. AIDS (2014) 0.92
Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Devel Ther (2015) 0.91
Retroviral DNA Integration. Chem Rev (2016) 0.90
Will drug resistance against dolutegravir in initial therapy ever occur? Front Pharmacol (2015) 0.90
Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS One (2013) 0.89
Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV. Infect Dis Ther (2014) 0.89
Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro. Antimicrob Agents Chemother (2015) 0.86
Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. J Virol (2014) 0.85
Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection. P T (2015) 0.84
The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir. Antimicrob Agents Chemother (2014) 0.83
Retroviral Integrase Structure and DNA Recombination Mechanism. Microbiol Spectr (2015) 0.83
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades. J Antimicrob Chemother (2015) 0.83
Role of Marine Natural Products in the Genesis of Antiviral Agents. Chem Rev (2015) 0.82
Raltegravir in HIV-1 infection: Safety and Efficacy in Treatment-naïve Patients. Clin Med Rev Ther (2011) 0.80
Pharmacokinetic determinants of virological response to raltegravir in the in vitro pharmacodynamic hollow-fiber infection model system. Antimicrob Agents Chemother (2015) 0.79
Correlating Drug-Target Kinetics and In vivo Pharmacodynamics: Long Residence Time Inhibitors of the FabI Enoyl-ACP Reductase. Chem Sci (2016) 0.78
Potential benefit of dolutegravir once daily: efficacy and safety. HIV AIDS (Auckl) (2013) 0.78
Rous sarcoma virus synaptic complex capable of concerted integration is kinetically trapped by human immunodeficiency virus integrase strand transfer inhibitors. J Biol Chem (2014) 0.78
Multifunctional facets of retrovirus integrase. World J Biol Chem (2015) 0.78
Different Pathways Leading to Integrase Inhibitors Resistance. Front Microbiol (2017) 0.77
The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica (Cairo) (2012) 0.76
Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. J Antimicrob Chemother (2015) 0.76
HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase. Antimicrob Agents Chemother (2014) 0.76
Dolutegravir: clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis (2014) 0.76
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Can J Infect Dis Med Microbiol (2016) 0.75
Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site. Nucleic Acids Res (2016) 0.75
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK. J Int AIDS Soc (2016) 0.75
HIV-1 resistance to dolutegravir: update and new insights. J Virus Erad (2015) 0.75
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. AIDS Res Ther (2016) 0.75
HIV-1 resistance to dolutegravir is affected by cellular histone acetyltransferase activity. J Virol (2017) 0.75
Impact of HIV-1 Integrase L74F/V75I Mutations from a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors. Antimicrob Agents Chemother (2017) 0.75
Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors. MBio (2017) 0.75
Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (1985) 30.62
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 7.01
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Retroviral intasome assembly and inhibition of DNA strand transfer. Nature (2010) 4.99
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr (2007) 4.67
Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov (2006) 4.56
Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol (1992) 3.85
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother (2010) 2.89
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol (2007) 2.33
HIV integrase, a brief overview from chemistry to therapeutics. J Biol Chem (2001) 2.33
Genetic analysis of the human immunodeficiency virus type 1 integrase protein. J Virol (1994) 2.26
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol (2009) 2.19
Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A (2010) 2.16
HIV integrase structure and function. Adv Virus Res (1999) 2.08
HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res (1999) 2.06
The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res (2009) 2.00
Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol (2011) 1.87
Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol (2008) 1.83
Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev (2009) 1.76
Resistance to integrase inhibitors. Viruses (2010) 1.75
Structure and function of HIV-1 integrase. Curr Top Med Chem (2004) 1.74
Retroviral DNA integration--mechanism and consequences. Adv Genet (2005) 1.66
Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res (2009) 1.64
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS (2011) 1.62
Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother (2009) 1.50
Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry (2010) 1.38
Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res (2008) 1.36
The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors. Biochemistry (2008) 1.21
Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J Biol Chem (2007) 1.13
Authentic HIV-1 integrase inhibitors. Future Med Chem (2010) 1.04
Synthesis and HIV-integrase strand transfer inhibition activity of 7-hydroxy[1,3]thiazolo[5,4-b]pyridin-5(4H)-ones. Bioorg Med Chem Lett (2006) 1.04
Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem (2008) 0.98
Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant. Biochemistry (2009) 0.97
Selection and analysis of HIV-1 integrase strand transfer inhibitor resistant mutant viruses. Methods (2009) 0.93
Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration. Methods (2009) 0.80
Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol (2009) 3.01
In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother (2010) 2.89
Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science (2013) 2.74
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol (2011) 1.95
In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother (2003) 1.83
Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev (2009) 1.68
Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res (2008) 1.61
Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086. J Biol Chem (2008) 1.38
Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res (2008) 1.36
The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr (2012) 1.30
Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors. J Biol Chem (2001) 1.26
Crystallization of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr (2006) 1.23
Development of an automated large-scale protein-crystallization and monitoring system for high-throughput protein-structure analyses. Acta Crystallogr D Biol Crystallogr (2006) 1.22
Association between amygdala response to emotional faces and social anxiety in autism spectrum disorders. Neuropsychologia (2010) 1.21
The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob Agents Chemother (2007) 1.21
Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-beta type I receptor inhibitors. J Med Chem (2004) 1.20
Cold-induced activation of brown adipose tissue and adipose angiogenesis in mice. Nat Protoc (2012) 1.14
Cold exposure promotes atherosclerotic plaque growth and instability via UCP1-dependent lipolysis. Cell Metab (2013) 1.12
Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744). J Med Chem (2013) 1.09
Expression, preparation, and high-throughput screening of caspase-8: discovery of redox-based and steroid diacid inhibition. Arch Biochem Biophys (2002) 1.09
Formation of a highly ordered dot array of surface micelles of a block copolymer via liquid crystal-hybridized self-assembly. Langmuir (2006) 1.07
Enzymological analysis of mutant protein kinase Cgamma causing spinocerebellar ataxia type 14 and dysfunction in Ca2+ homeostasis. J Biol Chem (2008) 1.06
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer Res (2008) 1.04
Synthesis and HIV-integrase strand transfer inhibition activity of 7-hydroxy[1,3]thiazolo[5,4-b]pyridin-5(4H)-ones. Bioorg Med Chem Lett (2006) 1.04
Limited role for SREBP-1c in defective glucose-induced insulin secretion from Zucker diabetic fatty rat islets: a functional and gene profiling analysis. Am J Physiol Endocrinol Metab (2006) 1.03
TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J Biol Chem (2007) 1.01
Heparin-like glycosaminoglycans prevent the infection of measles virus in SLAM-negative cell lines. Antiviral Res (2008) 1.01
Hypoxic stress activates chaperone-mediated autophagy and modulates neuronal cell survival. Neurochem Int (2012) 0.99
N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett (2006) 0.99
Preparatory activity in occipital cortex in early blind humans predicts auditory perceptual performance. J Neurosci (2007) 0.99
Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. Nat Commun (2013) 0.98
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. J Med Chem (2004) 0.98
Synergy effect on morphology switching: real-time observation of photo-orientation of microphase separation in a block copolymer. Angew Chem Int Ed Engl (2012) 0.98
Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant. Biochemistry (2009) 0.97
Imidazo[1,2-a]pyridines with potent activity against herpesviruses. Bioorg Med Chem Lett (2007) 0.96
Photoregulated wormlike motion of a gel. Angew Chem Int Ed Engl (2008) 0.96
Crystal structure of purine nucleoside phosphorylase from Thermus thermophilus. J Mol Biol (2004) 0.96
Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs. Nucleic Acid Ther (2012) 0.95
Clinical characteristics of eight patients with congenital nephrogenic diabetes insipidus. Endocrine (2004) 0.95
4-Vinyl-2,6-dimethoxyphenol (canolol) suppresses oxidative stress and gastric carcinogenesis in Helicobacter pylori-infected carcinogen-treated Mongolian gerbils. Int J Cancer (2008) 0.94
Polymeric micelles of zinc protoporphyrin for tumor targeted delivery based on EPR effect and singlet oxygen generation. J Drug Target (2007) 0.94
The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. J Ovarian Res (2014) 0.92
Clinical and molecular analysis of GM2 gangliosidosis in two apparent littermate kittens of the Japanese domestic cat. J Feline Med Surg (2007) 0.92
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem (2012) 0.92
TNFAIP3 promotes survival of CD4 T cells by restricting MTOR and promoting autophagy. Autophagy (2015) 0.91
Mutant PKCγ in spinocerebellar ataxia type 14 disrupts synapse elimination and long-term depression in Purkinje cells in vivo. J Neurosci (2011) 0.91
Synthesis of novel imidazo[1,2-a]pyridines with potent activity against herpesviruses. Org Lett (2003) 0.90
Measurement of laparoscopic skills in microgravity anticipates the space surgeon. Am J Surg (2004) 0.90
Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics. PLoS One (2013) 0.89
Angle-independent structural color in colloidal amorphous arrays. Chemphyschem (2010) 0.89
Halothane-induced liver injury is mediated by interleukin-17 in mice. Toxicol Sci (2009) 0.89
Measles virus induces cell-type specific changes in gene expression. Virology (2008) 0.89
Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity. Bioorg Med Chem Lett (2008) 0.88
Pharmacovirological impact of an integrase inhibitor on human immunodeficiency virus type 1 cDNA species in vivo. J Virol (2009) 0.88
Allelopathy and allelopathic substance in the moss Rhynchostegium pallidifolium. J Plant Physiol (2010) 0.87
An intrinsic ATPase activity of phospho-MEK-1 uncoupled from downstream ERK phosphorylation. Arch Biochem Biophys (2007) 0.87
Carbamoyl pyridone HIV-1 integrase inhibitors. 2. Bi- and tricyclic derivatives result in superior antiviral and pharmacokinetic profiles. J Med Chem (2013) 0.87
Production of colored pigments with amorphous arrays of black and white colloidal particles. Angew Chem Int Ed Engl (2013) 0.87
Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice. Antimicrob Agents Chemother (2013) 0.86
Identification of a new family of spinocerebellar ataxia type 14 in the Japanese spinocerebellar ataxia population by the screening of PRKCG exon 4. Mov Disord (2006) 0.86
Significance of peak value and duration of the interfacial shear load in evaluation of the bone-implant interface. Clin Biomech (Bristol, Avon) (2003) 0.86
Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HT1A receptor. J Pharmacol Sci (2003) 0.86
High-density liquid-crystalline azobenzene polymer brush attained by surface-initiated ring-opening metathesis polymerization. Langmuir (2013) 0.86
Effects of the chemical chaperone 4-phenylbutylate on the function of the serotonin transporter (SERT) expressed in COS-7 cells. J Pharmacol Sci (2013) 0.86
Clinical magnetic resonance volumetry of the hippocampus in 58 epileptic dogs. Vet Radiol Ultrasound (2010) 0.85
Effects of continuous administration of paroxetine on ligand binding site and expression of serotonin transporter protein in mouse brain. Brain Res (2005) 0.85
Role of C-terminal region in the functional regulation of rat serotonin transporter (SERT). Neurochem Int (2004) 0.85
Involvement of alpha7- and alpha4beta2-type postsynaptic nicotinic acetylcholine receptors in nicotine-induced excitation of dopaminergic neurons in the substantia nigra: a patch clamp and single-cell PCR study using acutely dissociated nigral neurons. Brain Res Mol Brain Res (2004) 0.85
Structural colored gels for tunable soft photonic crystals. Chem Rec (2009) 0.83
Chemical and optical control of peristaltic actuator based on self-oscillating porous gel. Chem Commun (Camb) (2008) 0.83
Surface design for precise control of spatial growth of a mesostructured inorganic/organic film on a large-scale area. Langmuir (2007) 0.83
Extracellular ATP differentially modulates Toll-like receptor 4-mediated cell survival and death of microglia. J Neurochem (2011) 0.83
Imaging living mice using a 1-T compact MRI system. J Magn Reson Imaging (2006) 0.83
Initial pulmonary respiration causes massive diaphragm damage and hyper-CKemia in Duchenne muscular dystrophy dog. Sci Rep (2013) 0.83
In-hospital clinical outcomes of elderly patients (≥80 years) undergoing percutaneous coronary intervention. Circ J (2014) 0.83
Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase. Bioorg Med Chem Lett (2009) 0.83
Repeated administration of methamphetamine causes hypersensitivity of D2 receptor in rat ventral tegmental area. Neurosci Lett (2003) 0.83
Structural colored liquid membrane without angle dependence. ACS Appl Mater Interfaces (2009) 0.82
NMR dynamics and antibody recognition of the meningococcal lipidated outer membrane protein LP2086 in micellar solution. Biochim Biophys Acta (2009) 0.82
IL-4 mediates dicloxacillin-induced liver injury in mice. Toxicol Lett (2010) 0.82
Inhibition of wild-type and mutant human immunodeficiency virus type 1 proteases by GW0385 and other arylsulfonamides. Biochemistry (2004) 0.82
Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore. J Med Chem (2012) 0.82
Mutant protein kinase C gamma that causes spinocerebellar ataxia type 14 (SCA14) is selectively degraded by autophagy. Genes Cells (2010) 0.81
Liquid-crystalline polymer and block copolymer domain alignment controlled by free-surface segregation. Angew Chem Int Ed Engl (2013) 0.81
Organized monolayer of thermosensitive microgel beads prepared by double-template polymerization. Langmuir (2007) 0.81
Fabrication of mechanically improved hydrogels using a movable cross-linker based on vinyl modified polyrotaxane. Chem Commun (Camb) (2008) 0.81
Design of disulfide-linked thioredoxin dimers and multimers through analysis of crystal contacts. J Mol Biol (2007) 0.81